filmov
tv
In-vitro immunogenicity prediction [WEBINAR]
Показать описание
In vitro assays offer many benefits for early immunogenicity prediction and primary cells are a necessary component of such assays. Thorough planning with standardized and high quality cellular material can lead to more reliable results.
Miltenyi Biotec is a global provider of products and services that empower biomedical discovery and advance cellular therapy. Our innovative tools support research at every level, from basic research to translational research to clinical application. This integrated portfolio enables scientists and clinicians to obtain, analyze, and utilize the cell. Our technologies enable solutions for cellular research, cell therapy, cell manufacturing, and imaging. Our 30 years of expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer, and clinical research areas like hematology, graft engineering, and apheresis. In our commitment to the scientific community, we also offer comprehensive scientific support, consultation, and expert training. Today, Miltenyi Biotec has more than 3,000 employees in 28 countries – all dedicated to helping researchers and clinicians around the world make a greater impact on science and health.
Miltenyi Biotec is a global provider of products and services that empower biomedical discovery and advance cellular therapy. Our innovative tools support research at every level, from basic research to translational research to clinical application. This integrated portfolio enables scientists and clinicians to obtain, analyze, and utilize the cell. Our technologies enable solutions for cellular research, cell therapy, cell manufacturing, and imaging. Our 30 years of expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer, and clinical research areas like hematology, graft engineering, and apheresis. In our commitment to the scientific community, we also offer comprehensive scientific support, consultation, and expert training. Today, Miltenyi Biotec has more than 3,000 employees in 28 countries – all dedicated to helping researchers and clinicians around the world make a greater impact on science and health.
In-vitro immunogenicity prediction [WEBINAR]
Accelerate your biologics discovery with immunogenicity prediction [WEBINAR]
Tim Hickling: Applying in vitro immunogenicity assays to predict clinical immunogenicity
2020 User Workshop – 2.2 – T Cell Processing & Immunogenicity Predictions
Model Informed Drug Development Approaches for Immunogenicity Assessments Workshop
Mixed leukocyte reaction and other antigen-presentation assays [WEBINAR]
2022 User Workshop – 2.2 – T Cell Processing & Immunogenicity Predictions & Section 1 Q&...
2021 User Workshop – 2.2 – T Cell Processing & Immunogenicity Predictions
Non-clinical Evaluation of Immunogenicity Risk of Generic Complex Peptide Products
Predicting and Taming Immunogenicity: Strategies for your Biologic Drug
In-vitro/ex-vivo Assays to Predict Immune Stimulation, Immunogenicity, Immunotoxicity with Biologics
Predicting and Taming Immunogenicity: Overview of Immunogenicity & ADA Assays
Anti drug Antibody Analysis for Preclinical Studies
Model Informed Drug Development Approaches for Immunogenicity Assessments Workshop
Tim Hickling: Application of Immunogenicity Prediction and Mitigation for Biotherapeutic Development
Mike Zimmer: Engineering a less immunogenic bacterial protease for treatment of IgA Nephropathy
Daron Forman: The use of immunogenicity risk assessment tools for lead optimization of biologics
2023 User Workshop – 2.2 – T Cell Class I Tools (Binding, Processing, Immunogenicity)
Model Informed Drug Development Approaches for Immunogenicity Assessments Workshop
Model Informed Drug Development Approaches for Immunogenicity Assessments Workshop
CRRG Webinar: Understanding and harnessing the immune system
Webinar - Bispecific Antibodies: The Next Generation of Antibody Therapeutics
Bonnie Rup: Unwanted immunogenicity risk in biotherapeutic discovery and development
Model Informed Drug Development Approaches for Immunogenicity Assessments Workshop
Комментарии